GLP-1RA Lipid-Specific Outcomes While the GLP-1RAs used for weight loss, semaglutide and tirzepatide, have garnered much focus, multiple other GLP-1RA medications have shown positive outcomes on lipid profiles: dulaglutide has shown reduction in total cholesterol and LDL-C [65], liraglutide has shown reduction in LDL-C and ApoCIII [66], and exenatide has shown reduction in LDL-C and total cholesterol and increase in HDL-C [67]
Understanding the roles of TLR2 and TLR4 in doxorubicin-induced cardiac inflammation may lead to potential therapeutic strategies for managing cardiotoxicity in cancer treatment [92]
Like GLP-1 hormones, GIP hormones are triggered when you eat and increase insulin production
Notably, mutations in the GLUT2 gene affect the glucose-lowering efficacy of metformin (Zhou et al., 2016), which may be one of the reasons for individual differences in metformin efficacy
Once bound, it stimulates the release of growth hormone in natural pulses, similar to how your body would release it on its own
Adults (2019-2024) Prescription Patterns and Healthcare Provider Trends Advanced practice practitioners and primary care physicians increasingly prescribe these medications, with APPs' share rising from 25.3% to 40.6% between 2017 and 2024 ^22